Role of Dynamic Magnetic Resonance Imaging in the Evaluation of Tumor Response to Preoperative Concurrent Radiochemotherapy for Large Breast Cancers: A Prospective Phase II Study
- 1 September 2007
- journal article
- research article
- Published by Elsevier BV in International Journal of Radiation Oncology*Biology*Physics
- Vol. 69 (1), 13-18
- https://doi.org/10.1016/j.ijrobp.2007.02.020
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: Results of a phase II studyEuropean Journal of Cancer, 2006
- Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-AnalysisJNCI Journal of the National Cancer Institute, 2005
- Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survivalAnnals of Oncology, 2005
- MRI for Surgical Planning in Patients with Breast Cancer Who Undergo Preoperative ChemotherapyAmerican Journal of Roentgenology, 2004
- Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18JNCI Monographs, 2001
- Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902Journal of Clinical Oncology, 2001
- Primary Chemotherapy for Operable Breast Cancer: Incidence and Prognostic Significance of Ipsilateral Breast Tumor Recurrence After Breast-Conserving SurgeryJournal of Clinical Oncology, 2001
- Short and long‐term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trialBreast Cancer Research and Treatment, 1999
- Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-upAnnals of Oncology, 1999